Indaptus director Natan reports no share holdings
Indaptus Therapeutics, Inc. director David Natan filed an initial ownership report stating that he currently holds no shares of the company.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Indaptus Therapeutics, Inc. director David Natan filed an initial ownership report stating that he currently holds no shares of the company. The filing shows that he has no beneficial ownership of non-derivative or derivative securities of Indaptus as of the event date, and his position is reported as a director filing on his own behalf.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | No securities are beneficially owned. | -- | -- | -- |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the latest Form 3 for INDP show about David Natan?
What is David Natan’s relationship to Indaptus Therapeutics (INDP)?
What transaction information is included in this INDP Form 3 filing?
Are there any derivative securities reported for the INDP director?
AI-generated analysis. How Rhea-AI works. Not financial advice.